David I. Sandoval net worth and biography

David Sandoval Biography and Net Worth

Senior Vice President and General Counsel of MaxCyte

Mr. Sandoval has more than 20 years of experience in the biopharmaceutical industry. He served as Chief Legal Officer and Chief Compliance Officer at Leadiant Biosciences, Inc., and as Assistant General Counsel and Assistant Compliance Officer at Enzon Pharmaceuticals, Inc. In addition to his in-house experience, Mr. Sandoval began his legal career working at major U.S. law firms.

Mr. Sandoval is a member of the New York and New Jersey Bar and earned his Juris Doctor from New York University School of Law after completing his Bachelor of Arts from Cornell University.

What is David I. Sandoval's net worth?: The estimated net worth of David I. Sandoval is at least $101.47 thousand as of March 18th, 2025. Mr. Sandoval owns 64,219 shares of MaxCyte stock worth more than $101,466 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Sandoval may own. Learn More about David I. Sandoval's net worth.
How old is David I. Sandoval?: Mr. Sandoval is currently 46 years old. There are 6 older executives and no younger executives at MaxCyte. The oldest executive at MaxCyte is Dr. J. Stark Thompson Ph.D., Consultant, who is 82 years old. Learn More on David I. Sandoval's age.
How do I contact David I. Sandoval?: The corporate mailing address for Mr. Sandoval and other MaxCyte executives is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. MaxCyte can also be reached via phone at 301-944-1700 and via email at [email protected]. Learn More on David I. Sandoval's contact information.
Has David I. Sandoval been buying or selling shares of MaxCyte?: David I. Sandoval has not been actively trading shares of MaxCyte in the last ninety days. Most recently, David I. Sandoval sold 353 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $3.18, for a transaction totalling $1,122.54. Following the completion of the sale, the general counsel now directly owns 64,219 shares of the company's stock, valued at $204,216.42. Learn More on David I. Sandoval's trading history.
Who are MaxCyte's active insiders?: MaxCyte's insider roster includes Douglas Doerfler (Founder), Douglas Doerfler (Founder), Stanley Erck (Director), John Johnston (Director), Maher Masoud (CEO), David Sandoval (Senior Vice President and General Counsel), Ali Soleymannezhad (Insider), and Douglas Swirsky (CFO). Learn More on MaxCyte's active insiders.
Are insiders buying or selling shares of MaxCyte?: In the last year, MaxCyte insiders bought shares 5 times. They purchased a total of 355,000 shares worth more than $479,950.00. In the last year, insiders at the sold shares 7 times. They sold a total of 29,653 shares worth more than $95,594.74. The most recent insider tranaction occured on August, 13th when CFO Douglas J Swirsky bought 50,000 shares worth more than $64,500.00. Insiders at MaxCyte own 3.3% of the company. Learn More about insider trades at MaxCyte.
Information on this page was last updated on 8/13/2025.

David I. Sandoval Insider Trading History at MaxCyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/18/2025	Sell	353	$3.18	$1,122.54	64,219
1/13/2025	Sell	4,466	$4.54	$20,275.64	41,447

David I. Sandoval Buying and Selling Activity at MaxCyte

MaxCyte Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Today's Range

Now: $1.58

$1.50

$1.62

50 Day Range

MA: $1.62

$1.44

$1.83

2 Week Range

Now: $1.58

$1.26

$5.20

Volume

577,871 shs

Average Volume

856,912 shs

Market Capitalization

$168.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

David Sandoval Biography and Net Worth

What is David I. Sandoval's net worth?

How old is David I. Sandoval?

How do I contact David I. Sandoval?

Has David I. Sandoval been buying or selling shares of MaxCyte?

Who are MaxCyte's active insiders?

Are insiders buying or selling shares of MaxCyte?